UroGen Pharma Announces CFO Transition and Compensation Details
Company Announcements

UroGen Pharma Announces CFO Transition and Compensation Details

An announcement from Urogen Pharma ( (URGN) ) is now available.

UroGen Pharma Ltd. announced the departure of CFO Don Kim, who will continue to provide consulting services until April 2025 and has a benefits package including his salary and bonus. Concurrently, Christopher Degnan has been appointed the new CFO, bringing experience from various pharmaceutical firms. Degnan’s compensation includes a $500,000 base salary, potential bonuses, and equity awards with a vesting schedule, along with severance benefits in certain termination scenarios.

See more data about URGN stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyUroGen Pharma price target raised to $64 from $60 at H.C. Wainwright
TheFlyUroGen Pharma announces FDA acceptance of new drug application for UGN-102
TheFlyUroGen Pharma initiated with a Buy at EF Hutton
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App